WO2026057015 - RNAI AGENT USED FOR INHIBITING 17β-HSD13 GENE EXPRESSION, PREPARATION METHOD THEREFOR, AND USE
National phase entry is expected:
Publication Number
WO/2026/057015
Publication Date
19.03.2026
International Application No.
PCT/CN2025/120921
International Filing Date
12.09.2025
Title **
[English]
RNAI AGENT USED FOR INHIBITING 17β-HSD13 GENE EXPRESSION, PREPARATION METHOD THEREFOR, AND USE
[French]
AGENT À ARNI UTILISÉ POUR INHIBER L'EXPRESSION DU GÈNE 17β-HSD13, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
[Chinese]
用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
JIANG, Wenjuan
ZHANG, Weiji
LI, Jiani
WU, Junjun
LI, Lili
XIAO, Ying
LU, Yinsuo
Priority Data
202411301092.7
14.09.2024
CN
202411630306.5
14.11.2024
CN
202411814736.2
10.12.2024
CN
202510185443.0
18.02.2025
CN
202511001269.6
18.07.2025
CN
202511189234.X
22.08.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1967 | |
| EPO | Filing, Examination, Granting | 11551 | |
| Japan | Filing, Examination, Granting | 2122 | |
| South Korea | Filing, Examination, Granting | 2229 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,609
Contact Us
Abstract[English]
The present invention relates to an RNAi agent used for inhibiting 17β-HSD13 gene expression, a preparation method therefor, and a use. The RNAi agent is used for treating HSD17B13-related diseases and conditions, comprising NAFLD, NASH, liver fibrosis, or alcoholic liver disease or non-alcoholic liver disease such as cirrhosis.[French]
La présente invention concerne un agent à ARNi utilisé pour inhiber l'expression du gène 17β-HSD13, son procédé de préparation et son utilisation. L'agent à ARNi est utilisé pour traiter des maladies et des états liés à HSD17B13, comprenant NAFLD, NASH, la fibrose hépatique, ou une maladie hépatique alcoolique ou une maladie hépatique non alcoolique telle que la cirrhose.[Chinese]
本发明涉及一种用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途，所述RNAi剂用于治疗HSD17B13相关疾病和病症，所述疾病和病症包括NAFLD、NASH、肝纤维化、或者酒精性肝病或非酒精性肝病例如肝硬化。